Contents 3 min read

Claim and source comparison

Comparison limited to three human trial abstracts, one NGF laboratory abstract and LiverTox safety information. It does not establish completion of the clinical literature or independent medical review.

· Bounded source comparison; not a complete clinical review or independent medical endorsement.

Cell / laboratory study

Kawagishi et al. (1994) reported laboratory NGF-synthesis activity for erinacines A, B and C isolated from cultured mycelia. This does not show that oral mushroom products reach the human brain, increase NGF/BDNF or generate new neurons. Fruiting bodies, mycelia and isolated compounds are not equivalent.

Laboratory NGF synthesis with isolated erinacines is not measured NGF elevation or new-neuron formation in the human brain. This source does not rank clinical superiority of oral products.

Source 4 · Abstract read

Human randomized controlled trial

Mori et al. (2009) divided 30 people with mild cognitive impairment into two groups of 15. The active group took 3 g/day tablets containing 96% mushroom powder for 16 weeks; cognitive scale differences appeared at weeks 8, 12 and 16. This does not establish superior extracts or onset at 2–4 weeks.

This is a small trial of one product; cognitive scores fell during the four weeks after discontinuation. It does not establish lasting benefit, dementia prevention, effects in healthy young people or equivalence with other extracts. Authors have a mushroom-company affiliation.

Source 1 · Abstract read

Human randomized controlled trial

Nagano et al. (2010) randomized 30 women to mushroom or placebo cookies for four weeks. Some depression and complaint scores fell relative to personal baseline; placebo comparisons differed on selected complaint items.

Within-person change is not the same as superiority to placebo. This small, short study of a specific food product does not establish treatment of depression or an anxiety disorder.

Source 2 · Abstract read

Human randomized controlled trial

Docherty et al. (2023) studied 1.8 g/day for 28 days in 41 healthy adults. Stroop responses were faster 60 minutes after a single dose (P = 0.005); the day-28 subjective stress difference remained a trend (P = 0.051).

Null and limited negative findings were also reported; a selected-task difference is not general cognitive enhancement. P = 0.051 is not significant stress reduction at the 0.05 threshold. Sempera Organics supplied the product; this experiment does not establish personal onset or dosing.

Source 5 · Abstract read

Official safety summary

LiverTox describes gastrointestinal complaints and a reported acute hypersensitivity reaction for Lion’s Mane. Absence of an established link to clinical liver injury does not establish safety of every product or medication combination.

Few short trials do not exclude rare or long-term harm. This source does not establish pregnancy/breastfeeding safety or the magnitude of human interactions with anticoagulants and diabetes medicines.

Source 6 · Official summary read

Our evidence and source methodology

Lion's Mane: conceptual editorial illustration
Conceptual editorial artwork; not a research finding or evidence of clinical benefit in humans.

What is Lion's Mane?

Lion’s Mane (Hericium erinaceus) has been examined in small cognition and mood studies. NGF, BDNF and neuroplasticity findings are mostly cell or animal data; they do not establish human neurogenesis or dementia prevention.

Mechanism of Effect

Kawagishi et al. (1994) reported laboratory NGF-synthesis activity for erinacines A, B and C isolated from cultured mycelia. This does not show that oral mushroom products reach the human brain, increase NGF/BDNF or generate new neurons. Fruiting bodies, mycelia and isolated compounds are not equivalent.

Laboratory NGF synthesis with isolated erinacines is not measured NGF elevation or new-neuron formation in the human brain. This source does not rank clinical superiority of oral products.

Clinical Evidence

Mori et al. (2009) divided 30 people with mild cognitive impairment into two groups of 15. The active group took 3 g/day tablets containing 96% mushroom powder for 16 weeks; cognitive scale differences appeared at weeks 8, 12 and 16. This does not establish superior extracts or onset at 2–4 weeks.

This is a small trial of one product; cognitive scores fell during the four weeks after discontinuation. It does not establish lasting benefit, dementia prevention, effects in healthy young people or equivalence with other extracts. Authors have a mushroom-company affiliation.

Nagano et al. (2010) randomized 30 women to mushroom or placebo cookies for four weeks. Some depression and complaint scores fell relative to personal baseline; placebo comparisons differed on selected complaint items.

Within-person change is not the same as superiority to placebo. This small, short study of a specific food product does not establish treatment of depression or an anxiety disorder.

Docherty et al. (2023) studied 1.8 g/day for 28 days in 41 healthy adults. Stroop responses were faster 60 minutes after a single dose (P = 0.005); the day-28 subjective stress difference remained a trend (P = 0.051).

Null and limited negative findings were also reported; a selected-task difference is not general cognitive enhancement. P = 0.051 is not significant stress reduction at the 0.05 threshold. Sempera Organics supplied the product; this experiment does not establish personal onset or dosing.

Dose information and research limits

This dose information describes research or product context; it is not a personal prescription, established safe upper limit or efficacy guarantee for healthy people. Extracts and different formulations should not be treated as equivalent milligram for milligram.

A “dual-extract” label does not automatically mean both fruiting body and mycelium are included. Powder, mycelium and extracts are not equivalent; comparative clinical trials have not established a superior form for humans.

Safety and Side Effects

LiverTox describes gastrointestinal complaints and a reported acute hypersensitivity reaction for Lion’s Mane. Absence of an established link to clinical liver injury does not establish safety of every product or medication combination.

Few short trials do not exclude rare or long-term harm. This source does not establish pregnancy/breastfeeding safety or the magnitude of human interactions with anticoagulants and diabetes medicines.

Who Does It Interact With?

The sources on this page do not establish the size of proposed interactions with anticoagulants or diabetes medicines in humans. An absence of interactions should not be assumed; people taking regular medication should discuss combined use with a clinician or pharmacist.

Related research and reading

These links show explicit editorial topic connections; they do not confirm a mechanism, efficacy or the safety of combined use. News dates refer to the source or event.

Educational guides

Sources

  1. Mori K, et al. (2009). Improving effects of the mushroom Yamabushitake (Hericium erinaceus) on mild cognitive impairment: a double-blind placebo-controlled clinical trial. Phytotherapy Research, 23(3), 367–372. PubMed · PMID 18844328
  2. Nagano M, et al. (2010). Reduction of depression and anxiety by 4 weeks Hericium erinaceus intake. Biomedical Research, 31(4), 231–237. PubMed · PMID 20834180
  3. Lai PL, et al. (2013). Neurotrophic properties of the Lion's mane medicinal mushroom, Hericium erinaceus (Higher Basidiomycetes) from Malaysia. International Journal of Medicinal Mushrooms, 15(6), 539–554. PubMed · PMID 24266378
  4. Kawagishi H, et al. (1994). Erinacines A, B and C, strong stimulators of nerve growth factor (NGF)-synthesis, from the mycelia of Hericium erinaceum. Tetrahedron Letters, 35(10), 1569–1572. https://doi.org/10.1016/S0040-4039(00)76760-8 Publisher record · DOI · Elsevier
  5. Docherty S, Doughty FL, Smith EF. (2023). The Acute and Chronic Effects of Lion's Mane Mushroom Supplementation on Cognitive Function, Stress and Mood in Young Adults: A Double-Blind, Parallel Groups, Pilot Study. Nutrients, 15(22), 4842. PubMed · PMID 38004235
  6. NIH NIDDK. LiverTox: Lion’s Mane. https://www.ncbi.nlm.nih.gov/books/NBK599740/ NIH NIDDK / LiverTox

Link verification checks the identity of the publication; it does not constitute independent expert review of clinical claims. Our evidence and source methodology · Source directory

Frequently Asked Questions